# NCT04206319 (NCT04206319)

> Radium-223 in Biochemically Recurrent Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04206319
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Biochemical Recurrent Prostate Cancer
- Interventions: Radium-223; 18F Sodium Fluoride
- Enrollment: 19
- Primary outcome: changes in immune cell populations

## Indexed commentary on NCT04206319 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04206319